CONTEXT: Dietary fructose induces unfavorable lipid alterations in animal models and adult studies. Little is known regarding metabolic tolerance of dietary fructose in children. OBJECTIVES: The aim of the study was to evaluate whether dietary fructose alters plasma lipids in children with nonalcoholic fatty liver disease (NAFLD) and in healthy children. DESIGN AND SETTING: We performed a 2-d, crossover feeding study at the Inpatient Clinical Interaction Site of the Atlanta Clinical and Translational Science Institute at Emory University Hospital. PARTICIPANTS AND INTERVENTION: Nine children with NAFLD and 10 matched controls without NAFLD completed the study. We assessed plasma lipid levels over two nonconsecutive, randomly assigned, 24-h periods under isocaloric, isonitrogenous conditions with three macronutrient-balanced, consecutive meals and either: 1) a fructose-sweetened beverage (FB); or 2) a glucose beverage (GB) being consumed with each meal. MAIN OUTCOME MEASURES: Differences in plasma glucose, insulin, triglyceride, apolipoprotein B, high-density lipoprotein cholesterol, and nonesterified free fatty acid levels were assessed using mixed models and 24-h incremental areas under the time-concentration curve. RESULTS: After FB, triglyceride incremental area under the curve was higher vs. after GB both in children with NAFLD (P = 0.011) and those without NAFLD (P = 0.027); however, incremental response to FB was greater in children with NAFLD than those without NAFLD (P = 0.019). For all subjects, high-density lipoprotein cholesterol declined in the postprandial and overnight hours with FB, but not with GB (P = 0.0006). Nonesterified fatty acids were not impacted by sugar but were significantly higher in NAFLD. CONCLUSIONS: The dyslipidemic effect of dietary fructose occurred in both healthy children and those with NAFLD; however, children with NAFLD demonstrated increased sensitivity to the impact of dietary fructose.
RCT Entities:
CONTEXT: Dietary fructose induces unfavorable lipid alterations in animal models and adult studies. Little is known regarding metabolic tolerance of dietary fructose in children. OBJECTIVES: The aim of the study was to evaluate whether dietary fructose alters plasma lipids in children with nonalcoholic fatty liver disease (NAFLD) and in healthy children. DESIGN AND SETTING: We performed a 2-d, crossover feeding study at the Inpatient Clinical Interaction Site of the Atlanta Clinical and Translational Science Institute at Emory University Hospital. PARTICIPANTS AND INTERVENTION: Nine children with NAFLD and 10 matched controls without NAFLD completed the study. We assessed plasma lipid levels over two nonconsecutive, randomly assigned, 24-h periods under isocaloric, isonitrogenous conditions with three macronutrient-balanced, consecutive meals and either: 1) a fructose-sweetened beverage (FB); or 2) a glucose beverage (GB) being consumed with each meal. MAIN OUTCOME MEASURES: Differences in plasma glucose, insulin, triglyceride, apolipoprotein B, high-density lipoprotein cholesterol, and nonesterifiedfree fatty acid levels were assessed using mixed models and 24-h incremental areas under the time-concentration curve. RESULTS: After FB, triglyceride incremental area under the curve was higher vs. after GB both in children with NAFLD (P = 0.011) and those without NAFLD (P = 0.027); however, incremental response to FB was greater in children with NAFLD than those without NAFLD (P = 0.019). For all subjects, high-density lipoprotein cholesterol declined in the postprandial and overnight hours with FB, but not with GB (P = 0.0006). Nonesterifiedfatty acids were not impacted by sugar but were significantly higher in NAFLD. CONCLUSIONS: The dyslipidemic effect of dietary fructose occurred in both healthy children and those with NAFLD; however, children with NAFLD demonstrated increased sensitivity to the impact of dietary fructose.
Authors: Karen L Teff; Sharon S Elliott; Matthias Tschöp; Timothy J Kieffer; Daniel Rader; Mark Heiman; Raymond R Townsend; Nancy L Keim; David D'Alessio; Peter J Havel Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: B Lamarche; K D Uffelman; A Carpentier; J S Cohn; G Steiner; P H Barrett; G F Lewis Journal: J Clin Invest Date: 1999-04 Impact factor: 14.808
Authors: Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: Miriam B Vos; Ryan Colvin; Patricia Belt; Jean P Molleston; Karen F Murray; Philip Rosenthal; Jeffrey B Schwimmer; James Tonascia; Aynur Unalp; Joel E Lavine Journal: J Pediatr Gastroenterol Nutr Date: 2012-01 Impact factor: 2.839
Authors: Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson Journal: J Hepatol Date: 2018-02-02 Impact factor: 25.083
Authors: Laura G Sanchez-Lozada; Ana Andres-Hernando; Fernando E Garcia-Arroyo; Christina Cicerchi; Nanxing Li; Masanari Kuwabara; Carlos A Roncal-Jimenez; Richard J Johnson; Miguel A Lanaspa Journal: J Biol Chem Date: 2019-01-16 Impact factor: 5.157
Authors: Miriam B Vos; Jill L Kaar; Jean A Welsh; Linda V Van Horn; Daniel I Feig; Cheryl A M Anderson; Mahesh J Patel; Jessica Cruz Munos; Nancy F Krebs; Stavra A Xanthakos; Rachel K Johnson Journal: Circulation Date: 2016-08-22 Impact factor: 29.690
Authors: J S Sullivan; M T Le; Z Pan; C Rivard; K Love-Osborne; K Robbins; R J Johnson; R J Sokol; S S Sundaram Journal: Pediatr Obes Date: 2014-06-24 Impact factor: 4.000